Resistance Less Common Among Transplant Recipients Treated With Maribavir For Cytomegalovirus, Research Suggests

Healio (8/14, Stulpin) writes, “Among transplant recipients being treated for cytomegalovirus, resistance was less common among those treated with maribavir vs. those treated with investigator-assigned standard therapy, researchers reported.” The findings...